8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2004

               Shire Pharmaceuticals Group plc               
(Exact name of registrant as specified in its charter)

                           England and Wales                           
(State or other jurisdiction of incorporation)

0-29630
(Commission File Number) 98-0359573
(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
                           Hampshire RG24 8EP England                           
(Address of principal executive offices)    (Zip code)

Registrant's telephone number, including area code         44 1256 894 000

______________________________________________________________________
(Former name or former address, if changed since last report)

Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and which is incorporated by reference herein.

Item 7. Financial Statements and Exhibits

          (c) Exhibits. The following exhibit is filed herewith::

99.1 Press Release dated July 14, 2004

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PHARMACEUTICALS GROUP PLC
By:	/s/ A C Russell
	Name:  Angus Russell
	Title:    Chief Financial Officer

Dated: July 14, 2004

EXHIBIT INDEX

Number Description

99.1 Press Release dated July 14, 2004

EX-99.1

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com EXHIBIT 99.1

SECOND QUARTER 2004 RESULTS DATE NOTIFICATION – 29^th July

Basingstoke, UK – 14 July 2004 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce second quarter 2004 earnings on Thursday, 29 July 2004.

Results announcement time:	12:00 BST / 07:00 EST
Conference call time:	14:00 BST / 09:00 EST

Live conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live analyst and investor conference call at 14:00 BST/09:00 EST.

Please RSVP claire.rowell@fd.com (T: +44 (0)20 7269 7285).

The details of the conference call are as follows:

UK dial in	+44 (0)1452 569 393
US / Canada dial in	1866 4341 089
Password	Shire Pharmaceuticals

Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:
A replay of the presentation will be available for 1 week. Details are as follows:

UK dial in	+44 (0)1452 550 000
Pin code	1589284#
US dial in	1866 247 4222
Pin code	1589284#
Webcast Replay	www.shire.com, in the investor relations section

If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160

End

For further information please contact:
Souheil Salah – Investor Relations	+44 (0)1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.